: Solid units that rapidly disintegrate or dissolve directly in the mouth without water.
Unless otherwise stated in the individual monograph, tablets must be stored:
The "Production" section of Monograph 0478 mandates specific in-process controls to maintain structural and microbiological safety:
Designed to change the rate, place, or time of drug release (e.g., prolonged or delayed release).
The European Pharmacopoeia does not exist in isolation. To reduce redundancy and facilitate global drug development, the Ph. Eur. works closely with the and the Japanese Pharmacopoeia (JP) through the Pharmacopoeial Discussion Group (PDG) and the ICH Q4B process. This collaboration aims to harmonize key general chapters.
This measures how quickly a tablet breaks down in liquid. Standard uncoated tablets must typically disintegrate within 15 minutes in water, while film-coated tablets are allowed up to 30 minutes .
The establishes the legally binding European Pharmacopoeia quality standards for manufacturing, testing, and distributing oral solid dosage forms. Maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , this general text dictates the legal and scientific benchmarks that any pharmaceutical product marketed within the signatory states must satisfy.
: Delayed-release tablets intended to resist gastric fluid and release the active substance in the intestinal tract.
The European Pharmacopoeia (Ph. Eur.) is a publication that sets standards for the quality, purity, and strength of medicines in Europe. The monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets, which are a widely used dosage form for administering medicinal products.
Must show no signs of disintegration or cracks when exposed to 0.1 M hydrochloric acid for 2 hours, but must disintegrate in a phosphate buffer solution (pH 6.8) within 60 minutes.
The label must explicitly state specific modifications (e.g., "gastro-resistant" or "modified-release"), specific instructions for use (e.g., "chew before swallowing" or "dissolve in water"), and any relevant storage declarations (e.g., "protect from moisture"). 6. The Role of Monograph 0478 in Global Harmonization
It defines the tablet fundamentally: "Solid preparations each containing a single dose of one or more active substances." But the brilliance of the monograph lies in how it navigates the variety of this format.
Monograph 0478 distinguishes several specific categories, each with tailored requirements:
The heart of Monograph 0478 lies in its mandated quality control tests. These tests are designed to guarantee that every batch of tablets meets predefined criteria for identity, purity, and performance.
: Active components are blended with diluents, binders, disintegrating agents, glidants, lubricants, coloring agents, or flavoring agents to ensure structural integrity and stability. Categories of Oral Tablets
: Solid units that rapidly disintegrate or dissolve directly in the mouth without water.
Unless otherwise stated in the individual monograph, tablets must be stored:
The "Production" section of Monograph 0478 mandates specific in-process controls to maintain structural and microbiological safety:
Designed to change the rate, place, or time of drug release (e.g., prolonged or delayed release). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The European Pharmacopoeia does not exist in isolation. To reduce redundancy and facilitate global drug development, the Ph. Eur. works closely with the and the Japanese Pharmacopoeia (JP) through the Pharmacopoeial Discussion Group (PDG) and the ICH Q4B process. This collaboration aims to harmonize key general chapters.
This measures how quickly a tablet breaks down in liquid. Standard uncoated tablets must typically disintegrate within 15 minutes in water, while film-coated tablets are allowed up to 30 minutes .
The establishes the legally binding European Pharmacopoeia quality standards for manufacturing, testing, and distributing oral solid dosage forms. Maintained by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , this general text dictates the legal and scientific benchmarks that any pharmaceutical product marketed within the signatory states must satisfy. : Solid units that rapidly disintegrate or dissolve
: Delayed-release tablets intended to resist gastric fluid and release the active substance in the intestinal tract.
The European Pharmacopoeia (Ph. Eur.) is a publication that sets standards for the quality, purity, and strength of medicines in Europe. The monograph for Tablets (0478) provides a comprehensive set of specifications for the testing and evaluation of tablets, which are a widely used dosage form for administering medicinal products.
Must show no signs of disintegration or cracks when exposed to 0.1 M hydrochloric acid for 2 hours, but must disintegrate in a phosphate buffer solution (pH 6.8) within 60 minutes. To reduce redundancy and facilitate global drug development,
The label must explicitly state specific modifications (e.g., "gastro-resistant" or "modified-release"), specific instructions for use (e.g., "chew before swallowing" or "dissolve in water"), and any relevant storage declarations (e.g., "protect from moisture"). 6. The Role of Monograph 0478 in Global Harmonization
It defines the tablet fundamentally: "Solid preparations each containing a single dose of one or more active substances." But the brilliance of the monograph lies in how it navigates the variety of this format.
Monograph 0478 distinguishes several specific categories, each with tailored requirements:
The heart of Monograph 0478 lies in its mandated quality control tests. These tests are designed to guarantee that every batch of tablets meets predefined criteria for identity, purity, and performance.
: Active components are blended with diluents, binders, disintegrating agents, glidants, lubricants, coloring agents, or flavoring agents to ensure structural integrity and stability. Categories of Oral Tablets
